Nothing Special   »   [go: up one dir, main page]

AR012593A1 - SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents

SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT

Info

Publication number
AR012593A1
AR012593A1 ARP980101885A ARP980101885A AR012593A1 AR 012593 A1 AR012593 A1 AR 012593A1 AR P980101885 A ARP980101885 A AR P980101885A AR P980101885 A ARP980101885 A AR P980101885A AR 012593 A1 AR012593 A1 AR 012593A1
Authority
AR
Argentina
Prior art keywords
hydrogen
substituted
phenyl
alkoxy
halogen
Prior art date
Application number
ARP980101885A
Other languages
Spanish (es)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR012593A1 publication Critical patent/AR012593A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pirrolopiridinas substituidas de formula (I), en la cual: R1 es amino, alquilamino C1-5, dialquilamino C1-5, hidroxi, alcoxi C1-5,alquilcarbonilamino C1-5, fenilcarbonilamino sustituido donde los sustituyentes fenilo se seleccionan entre elgrup o que consiste en halogeno, hidrogeno,alquilo C1-5 y alcoxi C1-5, arilalquilamino C1-3 o R7R8NCH=N-,donde R7 y R8 son seleccionados independientemente entre el grupo que consiste en hidrogeno yalquilo C1-5; R2 es hidrogeno, halogeno,fenilalquilo C1-5 o fenilalquilo sustituido donde los sustituyentes fenilo se seleccionan entre el grupo queconsiste en halogeno, hidrogeno, alcoxi C1-5 y alquilo C1-5; R3 es hidrogeno, alcoxi C1-5, feniloxi sustituido, (donde lossustituyentes fenilo se seleccionan entre el grupo que consiste en halogeno, hidrogeno, alcoxi C1-5), fenilalquiloxi sustituido C1-5 (donde los sustituyentes fenilo se seleccionanentre el grupo que consiste en halogeno, hidrogeno, alcoxi C1-5 yalquilo C-15) ; R4 es -N- o -C-; R5 es fenilo o fenilo sustituido donde los sustiyentesse seleccionan entre uno a tres miembros del grupo que consiste en halogeno, alquilo C1-5 y alcoxi C1-5; R6 es hidrogeno, alquilo C1-5 o dialquilaminoC1-5; ylas sales farmacéuticamente a ceptables de los mismos; composiciones farmacéuticas que las contienen, procedimiento para su preparacion, el uso delos mismos en la manufactura de un medicamento e intermediarios utilizados en su fabricacion.Los compuestos inhiben la produ ccion de una cantidad decitocinas inflamatorias, son utiles en el tratamiento de enfermedades asociadas.Substituted pyrrolopyridines of formula (I), in which: R1 is amino, C1-5 alkylamino, C1-5 dialkylamino, hydroxy, C1-5 alkoxy, C1-5 alkylcarbonylamino, substituted phenylcarbonylamino where phenyl substituents are selected from the group or it consists of halogen, hydrogen, C1-5alkyl, and C1-5alkoxy, arylalkyl-C1-3alkyl, or R7R8NCH = N-, where R7 and R8 are independently selected from the group consisting of hydrogen and C1-5alkyl; R2 is hydrogen, halogen, phenyl-C1-5-alkyl or substituted phenylalkyl where the phenyl substituents are selected from the group consisting of halogen, hydrogen, C1-5-alkoxy and C1-5-alkyl; R3 is hydrogen, C1-5 alkoxy, substituted phenyloxy, (where phenyl substituents are selected from the group consisting of halogen, hydrogen, C1-5 alkoxy), substituted phenyl-C1-5alkyloxy (where phenyl substituents are selected from the group consisting of in halogen, hydrogen, C1-5 alkoxy and C-15 alkyl); R4 is -N- or -C-; R5 is phenyl or substituted phenyl where the substituents are selected from one to three members from the group consisting of halogen, C1-5 alkyl, and C1-5 alkoxy; R6 is hydrogen, C1-5 alkyl, or C1-5 dialkylamino; and the pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing them, procedure for their preparation, their use in the manufacture of a medicine and intermediates used in their manufacture. The compounds inhibit the production of a quantity of inflammatory cytokines, they are useful in the treatment of associated diseases.

ARP980101885A 1997-04-24 1998-04-23 SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT AR012593A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4424497P 1997-04-24 1997-04-24

Publications (1)

Publication Number Publication Date
AR012593A1 true AR012593A1 (en) 2000-11-08

Family

ID=21931293

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101885A AR012593A1 (en) 1997-04-24 1998-04-23 SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT

Country Status (4)

Country Link
AR (1) AR012593A1 (en)
AU (1) AU7132998A (en)
WO (1) WO1998047899A1 (en)
ZA (1) ZA983452B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166048A (en) * 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US6180643B1 (en) 1996-11-19 2001-01-30 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
ATE267200T1 (en) 1997-10-20 2004-06-15 Hoffmann La Roche BICYCLIC KINASE INHIBITORS
IL136045A0 (en) * 1997-11-14 2001-05-20 Sankyo Co Pyridylpyrrole derivatives and pharmaceutical compositions containing the same
AU4694999A (en) * 1998-08-06 2000-02-28 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
EP1126852B1 (en) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6608072B1 (en) * 1999-10-27 2003-08-19 Novartis Ag Thiazole compounds and their pharmaceutical use
MXPA02006338A (en) 1999-12-24 2002-12-13 Aventis Pharma Ltd Azaindoles.
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
WO2001057018A1 (en) * 2000-02-02 2001-08-09 Abbott Laboratories Azaazulene inhibitors of p38 map kinase and tnf-alpha
PE20020506A1 (en) * 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
DE60316542T2 (en) 2002-03-28 2008-07-03 Eisai R&D Management Co., Ltd. 7-AZAINDOLE AS INHIBITORS C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDER
SG135051A1 (en) * 2002-06-20 2007-09-28 Aventis Pharma Ltd Azaindoles
CA2492033A1 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP2295433A3 (en) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
WO2004101565A2 (en) 2003-05-16 2004-11-25 Eisai Co., Ltd. Jnk inhibitors
ES2453367T3 (en) * 2003-11-19 2014-04-07 Array Biopharma, Inc. MEK heterocyclic inhibitors
JP5138938B2 (en) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Compounds and methods for the development of RET modulators
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
WO2007049820A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CL2007002617A1 (en) 2006-09-11 2008-05-16 Sanofi Aventis COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRAZIN-6-ILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFLAMMATION OF THE ARTICULATIONS, Rheumatoid Arthritis, TUMORS, LYMPHOMA OF THE CELLS OF THE MANTO.
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8119637B2 (en) * 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
CN105237530A (en) 2009-04-03 2016-01-13 豪夫迈罗氏公司 Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TR201816421T4 (en) 2011-02-07 2018-11-21 Plexxikon Inc Compounds and methods for kinase modulation and their indications.
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
US20130158049A1 (en) * 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
FR3001219A1 (en) * 2013-01-22 2014-07-25 Centre Nat Rech Scient KINASE INHIBITORS
EP3362450B1 (en) 2015-10-13 2020-07-01 Institut National de la Sante et de la Recherche Medicale (INSERM) N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699148B2 (en) * 1995-08-10 1998-11-26 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
WO1998047899A1 (en) 1998-10-29
AU7132998A (en) 1998-11-13
ZA983452B (en) 1999-10-25

Similar Documents

Publication Publication Date Title
AR012593A1 (en) SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT
HUP0203438A2 (en) 5-(2-substituted-5-heterocyclysulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0300894A2 (en) Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use
AR029383A1 (en) SMALL MOLECULES, THE INTERMEDIARIES FOR THEIR SYNTHESIS, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT INTENDED FOR TREATMENT OR PROPHYLAXIS OF INFLAMMATORY DISEASES OR MEDIATIONED BY IMMUNE CELLS
AR031680A1 (en) USE OF QUINUCLIDINE ACRYLAMIDS FOR THE PREPARATION OF MEDICINES, COMPOUNDS AND PHARMACEUTICAL COMPOSITION
AR036032A1 (en) COMPOUND DERIVED FROM QUINOLINA, COMPOSITION THAT INCLUDES IT; USE OF THE SAME IN THE MANUFACTURE OF MEDICINES, PROCESS TO PREPARE IT, AND METHOD TO DETECT AND SELECT AN AGENT THAT MODULATES THE ACTIVITY OF MIF
HUP0401307A2 (en) New indole derivatives with 5-ht6 receptor affinity, process for their preparation and pharmaceutical compositions containing them
ECSP066383A (en) DERIVATIVES OF 5-PHENYL-4-METHYL-TIAZOL-2-IL-AMINA AS INHIBITORS OF KINASA ENZYMES PHOSFATIDILINOSITOL 3 (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY ROUTES
AR063211A1 (en) DERIVATIVES OF 3- (PIRIDIN-3-IL) ACRILAMIDE AND 3- (PIRIDIN-3-IL) PROPIONAMIDE, A METHOD FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF ASSOCIATED DISEASES WITH THE VANILOID RECEIVER.
NO20055421L (en) Quinoline derivatives as phosphodiesterase inhibitors
CA2628131A1 (en) Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
CR7743A (en) NEW OXAZOL AND TIAZOL COMPOUNDS AS INHIBITOR OF THE TRANSFORMING GROWTH FACTOR (TGF)
ATE370138T1 (en) NEW IMIDAZOPYRIDINES AND THEIR USE
HUP0302474A2 (en) Therapeutically effective tropane derivatives, process for their preparation pharmaceutical compositions containing them and their use
HRP20041137B1 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
ATE557002T1 (en) COMPOUNDS WITH CALCIMETIC ACTION
UY29427A1 (en) SUBSTITUTED DERIVATIVES OF 2,3,4,5- TETRAHIDRO-1H-PIRIDO (4,3-B) INDOL, COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
AR035235A1 (en) HETEROCICLILOXI DERIVATIVES -, - TIOXI- AND -AMINOBENZAZOL AS 5-HYDROXITRIPTAMINE-6 LINES, A PROCEDURE FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
NO20070837L (en) Pyrido-pyrido pyrimidine derivatives, their preparation and therapeutic application for the treatment of cancer.
SE0300120D0 (en) Novel compounds
RU99101081A (en) MODE OF INTRODUCTION OF H +, K + -ATPASE INHIBITORS
AR054508A1 (en) BENCILPIPERAZINE COMPOSITE, ITS USE TO PREPARE A MEDICINAL PRODUCT, PROCEDURES FOR THE PREPARATION OF SUCH COMPOUND AND INTERMEDIATE COMPOUNDS, SUCH INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE IT
AR032607A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SALTS OF HYDROXIEICOSATETRAENOATE, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DRY EYE DISORDERS
HUP0003577A2 (en) Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them
AR007108A1 (en) ANTI-TUMOR AND ANTIVIRAL RENTAL AGENTS, PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH AGENTS.

Legal Events

Date Code Title Description
FB Suspension of granting procedure